No, I think that would be a great idea because it would reveal to Big Pharma that we are open and willing to partner with as our modus operandi, because our drug is multi-faceted and capable of augmenting their trial outcomes and results, cementing in convincingly low p values for them and helping them to get their drugs authorized much more easily in combination / adjuvant therapy than in a monotherapy approach..